Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18734628 | PREPARATION AND APPLICATION OF SUPRAMOLECULAR SELF-ASSEMBLED HYALURONIC ACID HYDROGEL | June 2024 | December 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18640722 | IMMUNOREGULATORY MOLECULES AND USES THEREFOR | April 2024 | June 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18621336 | COMPOSITIONS FOR TREATING MACULAR EDEMA | March 2024 | July 2025 | Abandon | 15 | 1 | 1 | Yes | No |
| 18605381 | PHARMACEUTICAL PREPARATION | March 2024 | August 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18534620 | ATF5 Peptide Variants and Uses Thereof | December 2023 | September 2024 | Allow | 10 | 0 | 1 | No | No |
| 18522766 | METHODS OF MODULATING ALK | November 2023 | January 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18513146 | METHODS FOR TREATING CANCER | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18504534 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA | November 2023 | December 2024 | Allow | 13 | 1 | 1 | No | No |
| 18503815 | METHODS FOR TREATING CANCER | November 2023 | September 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18496633 | USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT | October 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18461812 | Methods and Compositions for Treating Vasomotor Symptoms | September 2023 | March 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18455139 | COMPOUNDS FOR SELECTIVE DISRUPTION OF PROTEIN-PROTEIN INTERACTIONS | August 2023 | October 2025 | Allow | 26 | 2 | 1 | No | No |
| 18363416 | MATERIALS AND METHODS FOR EXTRACELLULAR VESICLE-ASSOCIATED DISEASES | August 2023 | January 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18215276 | METHODS AND COMPOSITIONS FOR IMPROVED COGNITION | June 2023 | November 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18298933 | CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USE | April 2023 | September 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18132517 | Methods and Compositions for Preventing or Minimizing Epithelial-Mesenchymal Transition | April 2023 | August 2024 | Abandon | 16 | 1 | 1 | No | No |
| 18192696 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | March 2023 | October 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18105293 | METHODS OF TREATING DISEASE WITH TERLIPRESSIN | February 2023 | March 2026 | Allow | 37 | 4 | 1 | Yes | No |
| 18163155 | Heparin-Associated Polypeptides and Uses Thereof | February 2023 | March 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18159363 | NUTRITIONAL FORMULA | January 2023 | January 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18063229 | METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES | December 2022 | August 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 18070224 | Micronutrient combination to reduce blood pressure | November 2022 | February 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 17994896 | Micronutrient combination to reduce blood pressure | November 2022 | June 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 17969971 | METHODS OF TREATING INFLAMMATORY SKIN DISORDERS | October 2022 | February 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17933276 | COMPOSITIONS AND METHODS FOR INHIBITING TUMOR-INDUCED IMMUNE SUPPRESSION | September 2022 | May 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17944998 | PEPTIDES AND PHARMACEUTICAL, NUTRACEUTICAL OR VETERINARY COMPOSITIONS FOR HAIR LOSS PREVENTION AND/OR TREATMENT | September 2022 | November 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17820230 | NOVEL COMPOUNDS (IMMUNORHELINS) | August 2022 | April 2024 | Abandon | 20 | 0 | 2 | Yes | No |
| 17889123 | FIBRONECTIN BASED SCAFFOLD PROTEINS | August 2022 | March 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17872552 | FAST-OFF RATE SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS | July 2022 | June 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17861839 | METHODS FOR TREATING CANCER | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17861838 | METHODS FOR TREATING CANCER | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17852263 | METHOD FOR PREPARING AMG 416 (ETELCALCETIDE) | June 2022 | April 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17851128 | ANTITUMOR PEPTIDE AND USE THEREOF | June 2022 | January 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17843676 | Heparin-Associated Polypeptides and Uses Thereof | June 2022 | October 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17784007 | METHOD FOR PREPARING PEPTIDE EMULSION FORMULATION | June 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17738362 | C3 FUSION PROTEIN AND METHODS OF MAKING AND USING THEREOF | May 2022 | October 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17774093 | PEPTIDE, COMPOSITION, AND METHOD FOR TREATING, PREVENTING, OR AMELIORATING MOOD DISORDER | May 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17773323 | SOLID COMPOSITIONS COMPRISING A PCSK9 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17705208 | PEPTIDOMIMETIC-BASED ANTIBODY SURROGATE FOR HER2 | March 2022 | July 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17697459 | HEMOSTATIC COMPOSITION AND HEMOSTATIC METHOD USING HEMOSTATIC COMPOSITION | March 2022 | September 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17685643 | PEPTIDE ENCAPSULATING FERRITIN | March 2022 | December 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17640133 | Human Recombinant Hyposialylated Erythropoietin, Methods of Purification and Therapeutic Uses Thereof | March 2022 | November 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17681380 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | February 2022 | March 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17675336 | NASAL DELIVERY | February 2022 | November 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17631793 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DAMAGE TO SKIN | January 2022 | May 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17630754 | MODIFIED MULTIMERIC BICYCLIC PEPTIDE LIGANDS | January 2022 | February 2026 | Abandon | 49 | 0 | 2 | No | No |
| 17579563 | Micronutrient combination to reduce blood pressure | January 2022 | November 2022 | Allow | 10 | 2 | 1 | Yes | No |
| 17579392 | NOVEL PROTEINS SPECIFIC FOR CD137 | January 2022 | November 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17627771 | METHODS FOR INDUCING FULL ABLATION OF HEMATOPOIESIS | January 2022 | February 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17627558 | PREBIOTIC-INDUCED ANTI-TUMOR IMMUNITY | January 2022 | March 2026 | Abandon | 50 | 2 | 1 | No | No |
| 17596099 | RECOMBINANT 4-1BB BINDING PROTEINS AND THEIR USE | December 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17614966 | PEPTIDES AND USES THEREOF | November 2021 | May 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17455831 | TARGETING DEREGULATED WNT SIGNALING IN CANCER USING STABILIZED ALPHA-HELICES OF BCL-9 | November 2021 | September 2025 | Allow | 46 | 4 | 1 | No | No |
| 17531182 | Ready-To-Use Carfilzomib Compositions | November 2021 | December 2023 | Abandon | 25 | 1 | 1 | No | No |
| 17612089 | METHODS OF TREATING MUSCULOSKELETAL DEFORMITIES IN QUADRUPED ANIMALS | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17611660 | Compositions and Methods for increasing Reproduction Performance in Non Human Mammals Using Recombinant Luteinizing Hormone | November 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17519637 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | November 2021 | October 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17605455 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | October 2021 | October 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17502952 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | October 2021 | May 2024 | Allow | 31 | 1 | 1 | No | No |
| 17491715 | VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS | October 2021 | December 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17594111 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | October 2021 | June 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17600198 | HYPOXIA-INDUCING CRYOGELS | September 2021 | October 2025 | Abandon | 49 | 2 | 1 | Yes | No |
| 17600221 | MONOMERIC PEPTIDE MULTI-AGONIST TARGETING THE GLP1 RECEPTOR AND NPY RECEPTORS | September 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17440698 | USE OF EPIDERMAL GROWTH FACTOR IN DIABETIC FOOT ULCER TREATMENT | September 2021 | June 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17476971 | BI-FUNCTIONAL ARGININE-GLYCINE-ASPARTIC ACID (RGD) PEPTIDES AND METHODS TO PROMOTE ANGIOGENESIS | September 2021 | January 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17593286 | DIRECT REPROGRAMMING OF CARDIAC FIBROBLASTS INTO CARDIOMYOCYTES USING AN ENDOTHELIAL CELL TRANSDIFFERENTIATION STRATEGY | September 2021 | January 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17438806 | MODULATION OF WNT SIGNALING IN AUDITORY DISORDERS | September 2021 | September 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17470976 | GLYCOCALYX MIMETIC COATINGS | September 2021 | September 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17462185 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | August 2021 | November 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17410743 | METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES | August 2021 | September 2022 | Allow | 13 | 2 | 1 | Yes | No |
| 17409642 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE | August 2021 | December 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17365530 | Methods and Compositions for Treating Vasomotor Symptoms | July 2021 | September 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17416484 | FUSION PROTEIN COMPRISING HUMAN LEFTY A PROTEIN VARIANTS AND USE THEREOF | June 2021 | November 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17351693 | PHI-4 POLYPEPTIDES AND METHODS FOR THEIR USE | June 2021 | September 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17347977 | NUTRITIONAL FORMULA | June 2021 | October 2022 | Allow | 16 | 2 | 1 | Yes | No |
| 17348106 | COMPOSITIONS AND METHODS FOR TREATING FRONTOTEMPORAL DEMENTIA | June 2021 | October 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17344378 | COLLAGEN REPLACEMENT/REGENERATION FORMULATION AND USES THEREOF | June 2021 | September 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17299841 | Erythropoietin Analogs For Veterinary Use | June 2021 | February 2025 | Abandon | 45 | 1 | 1 | Yes | No |
| 17294497 | ACTIVIN/BMP7 CHIMERAS: SUPER-ACTIVE SAB704 AND SAB715, AND THEIR RESPECTIVE NOGGINSENSITIZED VARIANTS, NAB704 AND NAB715; AND NAB204 | May 2021 | November 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17318706 | DETECTING AND TREATING CANCERS USING CELL PENETRANT MTP53-OLIGOMERIZATION-DOMAIN PEPTIDE | May 2021 | January 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17314629 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | May 2021 | October 2023 | Allow | 29 | 1 | 1 | No | No |
| 17246348 | PHARMACEUTICAL PREPARATION | April 2021 | December 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17290707 | TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF | April 2021 | October 2025 | Allow | 54 | 1 | 1 | Yes | No |
| 17290050 | SELF-ASSEMBLING PEPTIDES AND HYDROGELS | April 2021 | February 2026 | Allow | 57 | 2 | 1 | Yes | No |
| 17287398 | PREPARATION AND APPLICATION OF SUPRAMOLECULAR SELF-ASSEMBLED HYALURONIC ACID HYDROGEL | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17233157 | ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF | April 2021 | October 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17227943 | CANCER TREATMENT METHODS USING NANOFIBER STABILIZED GROWTH FACTORS | April 2021 | December 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 17218186 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES | March 2021 | August 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17215738 | METHODS FOR TREATMENT OF DISEASES | March 2021 | June 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17280541 | MODIFIED HUMAN ERYTHROPOIETIN | March 2021 | December 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17300085 | Children Blood Transfusion and Thymus Hormonal Therapy as Antiviral and Antibacterial Compounds | March 2021 | September 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17186757 | FOOD ADDITIVE TO ENHANCE ANIMAL PERFORMANCE AND METHOD OF USING THE SAME | February 2021 | May 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17183265 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | February 2021 | December 2025 | Abandon | 58 | 4 | 1 | Yes | No |
| 17269788 | Pharmaceutical Combination Comprising Epidermal Growth Factor and Secretagogue Peptide GHRP6 for the Restoration of Brain Damage | February 2021 | May 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17171841 | PROTEIN INTERFACES | February 2021 | November 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17265158 | NEUROPROTECTIVE COMPOSITIONS AND USE THEREOF | February 2021 | March 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17124301 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | December 2020 | December 2024 | Allow | 48 | 4 | 0 | Yes | No |
| 16953044 | COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS | November 2020 | June 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16951529 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA | November 2020 | August 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16949817 | NON-RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN CONCENTRATE | November 2020 | August 2024 | Allow | 45 | 3 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARTINEZ, TARA L.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MARTINEZ, TARA L works in Art Unit 1654 and has examined 362 patent applications in our dataset. With an allowance rate of 62.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner MARTINEZ, TARA L's allowance rate of 62.4% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MARTINEZ, TARA L receive 2.44 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MARTINEZ, TARA L is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +62.5% benefit to allowance rate for applications examined by MARTINEZ, TARA L. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.7% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 39.9% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 70.4% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.